Products & Services · Intangible Amortization

AstraZeneca milestone — Intangible Amortization

Insmed AstraZeneca milestone — Intangible Amortization increased by 244.8% to $818.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 244.8%, from $237.25K to $818.00K. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementSegment
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toD&A

How to read this metric

An increase reflects a larger base of amortizable assets, which reduces reported net income without impacting cash flow.

Detailed definition

This represents the periodic non-cash expense recognized to allocate the cost of intangible assets acquired through Astr...

Peer comparison

Comparable to amortization of acquired IPR&D or intangible assets reported by peers following the commercialization or regulatory approval of licensed products.

Metric ID: insm_segment_astrazeneca_milestone_amortization_of_intangible_assets

Historical Data

5 periods
 Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$237.25K$237.25K$237.25K$237.25K$818.00K
QoQ Change+0.0%+0.0%+0.0%+244.8%
YoY Change+244.8%
Range$237.25K$818.00K
CAGR+244.8%
Avg YoY Growth+244.8%
Median YoY Growth+244.8%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Insmed's astrazeneca milestone — intangible amortization?
Insmed (INSM) reported astrazeneca milestone — intangible amortization of $818.00K in Q1 2026.
How has Insmed's astrazeneca milestone — intangible amortization changed year-over-year?
Insmed's astrazeneca milestone — intangible amortization increased by 244.8% year-over-year, from $237.25K to $818.00K.
What does astrazeneca milestone — intangible amortization mean?
The non-cash expense recognized for the gradual consumption of intangible assets acquired through AstraZeneca milestones.